Literature DB >> 3503551

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D.

D M Slovik1, D I Rosenthal, S H Doppelt, J T Potts, M A Daly, J A Campbell, R M Neer.   

Abstract

Daily subcutaneous injection of a synthetic human parathyroid hormone fragment, combined with daily ingestion of 1,25(OH)2 vitamin D, significantly increased trabecular bone density in the spine (p less than .01), and improved intestinal calcium and phosphorus absorption and total body retention of dietary calcium and phosphorus in middle-aged men with idiopathic osteoporosis. The increases in spinal bone mineral were marked and progressive during a year of treatment. These results indicate that increasing intestinal absorption of dietary calcium while simultaneously stimulating new bone formation with small doses of parathyroid hormone can restore spinal bone in osteoporotic men.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3503551     DOI: 10.1002/jbmr.5650010411

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

1.  Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.

Authors:  Maria-Grazia Ascenzi; Vivian P Liao; Brittany M Lee; Fabrizio Billi; Hua Zhou; Robert Lindsay; Felicia Cosman; Jeri Nieves; John P Bilezikian; David W Dempster
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

Review 2.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 3.  Quantitative computed tomography: update 1987.

Authors:  H K Genant; P Steiger; J E Block; C C Glueer; B Ettinger; S T Harris
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

4.  Pulsatile secretion of parathyroid hormone and its action on a type I and type II PTH receptor: a hypothesis for understanding osteoporosis.

Authors:  R D Hesch; G Brabant; E F Rittinghaus; M J Atkinson; H Harms
Journal:  Calcif Tissue Int       Date:  1988-06       Impact factor: 4.333

Review 5.  Use of calciferol and its metabolites and analogues in osteoporosis. Current status.

Authors:  A M Parfitt
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

6.  Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures.

Authors:  E Canalis; M Centrella; W Burch; T L McCarthy
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

7.  In vitro response of neonatal condylar cartilage to simultaneous exposure to the parathyroid hormone fragments 1-34, 28-48, and 53-84 hPTH.

Authors:  M Silbermann; R Shurtz-Swirski; D Lewinson; P Shenzer; H Mayer
Journal:  Calcif Tissue Int       Date:  1991-04       Impact factor: 4.333

Review 8.  Bone mass measurement, fracture risk, and screening for osteoporosis.

Authors:  D I Rosenthal; A N Tosteson
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

Review 9.  Treatment of osteoporotic patients.

Authors:  C C Johnston
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

10.  Human parathyroid peptide treatment of vertebral osteoporosis.

Authors:  J Reeve; M E Arlot; J N Bradbeer; R Hesp; E Mcally; P J Meunier; J M Zanelli
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.